RESUMEN
OBJECTIVES: The National Health Service in England funds 12 months of weekly subcutaneous tocilizumab (qwTCZ) for patients with relapsing or refractory giant cell arteritis (GCA). During the COVID-19 pandemic, some patients were allowed longer treatment. We sought to describe what happened to patients after cessation of qwTCZ. METHODS: Multicentre service evaluation of relapse after stopping qwTCZ for GCA. The log-rank test was used to identify significant differences in time to relapse. RESULTS: 336 GCA patients were analysed from 40 centres, treated with qwTCZ for a median (interquartile range, IQR) of 12 (12-17) months. At time of stopping qwTCZ, median (IQR) prednisolone dose was 2 (0-5) mg/day. By 6, 12 and 24 months after stopping qwTCZ, 21.4%, 35.4% and 48.6% respectively had relapsed, requiring an increase in prednisolone dose to a median (IQR) of 20 (10-40) mg/day. 33.6% of relapsers had a major relapse as defined by EULAR. Time to relapse was shorter in those that had previously also relapsed during qwTCZ treatment (P = 0.0017); in those not in remission at qwTCZ cessation (P = 0.0036); and in those with large vessel involvement on imaging (P = 0.0296). Age ≥65, gender, GCA-related sight loss, qwTCZ treatment duration, TCZ taper, prednisolone dosing, and conventional synthetic DMARD use were not associated with time to relapse. CONCLUSION: Up to half our patients with GCA relapsed after stopping qwTCZ, often requiring a substantial increase in prednisolone dose. One third of relapsers had a major relapse. Extended use of TCZ or repeat treatment for relapse should be considered for these patients.
RESUMEN
AIM: The aim of the current study was to evaluate the dimensional accuracy of three various interocclusal recording materials. MATERIALS AND METHODS: A total of 90 disc-shaped samples were prepared using polyether paste, wax, and polyvinyl siloxane material with the support of stainless steel die. For the purposes of this investigation, three frequently utilized interocclusal recording materials were chosen, and 30 samples from each material were prepared. Group I: Bite registration using polyether paste; Group II: Bite registration using wax; Group III: Bite registration using polyvinyl siloxane material. No samples were exposed to direct sunlight during storage and were kept at room temperature. Using a 10x universal measuring microscope, each sample disc was examined for the presence of horizontal and vertical lines inscripted in the die. For each of the samples, readings were taken at different time periods of 24, 48, and 72 hours. RESULTS: After 24 hours, the less dimensional changes were found in polyether paste group (0.11 ± 0.07) followed by polyvinyl siloxane material group (0.19 ± 0.04) and wax group (0.25 ± 0.12). After 48 hours, the less dimensional changes were found in polyether paste group (0.34 ± 0.02) followed by polyvinyl siloxane material group (0.42 ± 0.01) and wax group (0.94 ± 0.12). After 72 hours, the least dimensional changes were found in polyether paste group (0.46 ± 0.14) followed by polyvinyl siloxane material group (0.92 ± 0.03) and wax group (1.14 ± 0.09). CONCLUSION: The present study concluded that both the material and time factors had an impact on dimensional stability. The most dimensionally stable group was the polyether paste group, which was followed by the polyvinyl siloxane and wax material groups. CLINICAL SIGNIFICANCE: Interocclusal recording material records the occlusal connection between real or artificial teeth for occlusal rehabilitation planning and for creating removable and fixed dentures. The creation of a clinically acceptable prosthesis is dependent upon the accuracy of the patient's diagnostic or working casts and the interocclusal record. How to cite this article: Sonkesriya S, Subramanian D, Saha P, et al. In Vitro Assessment of Dimensional Accuracy of Three Different Types of Interocclusal Recording Materials. J Contemp Dent Pract 2023;24(12):936-939.
Asunto(s)
Materiales de Impresión Dental , Siloxanos , Humanos , Registro de la Relación Maxilomandibular/métodos , PolivinilosRESUMEN
OBJECTIVE/BACKGROUND: Lower limb peripheral arterial disease (PAD) is becoming increasingly common. Lower limb perfusion, as determined by the ankle brachial pressure index (ABPI), is a recognised predictor of overall mortality. The increasing role of non-invasive imaging in patient assessment may aid in the ability to predict poor patient outcomes. METHODS: This study included all patients undergoing a lower limb arterial duplex over a period of 20 months. The site and burden of atherosclerosis within the lower limb was determined using the well validated Bollinger score. Patient demographic data were also collated. The primary outcome measure was all cause mortality. RESULTS: A total of 678 patients were included (median age 74 years). The overall median follow up period was 69.9 months. Of these, 307 patients reached the primary end point, which was death. Independent predictors of all cause mortality included total Bollinger score (odds ratio [OR] 1.11, 95% confidence interval [CI] 1.05-1.18 [p < .001]; OR per 10 points), femoropopliteal Bollinger score (OR 1.34, 95% CI 1.11-1.08 [p = .05]; OR per 10 points), and crural Bollinger score (OR 1.03, 95% CI 1.01-1.03 [p = .03]). There was also a significant association between mortality and age, a prior history of ischaemic heart disease, a history of congestive cardiac failure and chronic renal failure (chronic kidney disease ≥ 3). Statin and antiplatelet therapy were protective. CONCLUSION: This contemporary study confirms poor long-term outcomes still exist in patients with PAD. The site and severity of lower limb atherosclerosis are independent predictors of long-term mortality.
Asunto(s)
Aterosclerosis/mortalidad , Pierna/irrigación sanguínea , Enfermedad Arterial Periférica/mortalidad , Anciano , Anciano de 80 o más Años , Aterosclerosis/diagnóstico por imagen , Femenino , Humanos , Pierna/diagnóstico por imagen , Masculino , Persona de Mediana Edad , Enfermedad Arterial Periférica/diagnóstico por imagen , Estudios Retrospectivos , Factores de Riesgo , Tasa de Supervivencia , Ultrasonografía Doppler DúplexRESUMEN
This guideline will provide up-to-date, evidence-based recommendations on the safe use of non-biologic DMARDs, also called conventional synthetic DMARDs (csDMARD), across the full spectrum of autoimmune rheumatic diseases. The guideline will update the guideline published in 2017 and will be expanded to include people of all ages. Updated information on the monitoring of DMARDs and vaccinations will be included. The guideline will be developed using the methods and processes described in the British Society for Rheumatology's 'Creating clinical guidelines: our protocol', updated 2023.
RESUMEN
BACKGROUND: Giant cell arteritis is a large vessel vasculitis of the arteries in the head and neck. The mainstay of management is with high-dose corticosteroids, and patients often face difficulties stopping or reducing steroids without recurrence of symptoms. Corticosteroids are well established to have numerous associated side effects, including osteoporosis, weight gain, and diabetes. Therefore, when tocilizumab was approved for up to 1 year for cases of relapsing or refractory giant cell arteritis by the National Institute of Health and Care Excellence (NICE) in April 2018, this offered an opportunity to benefit from new funding and to reduce steroid burden. CASE PRESENTATION: This case series describes the impact of the establishment of a new hub and spoke referral pathway for the use of tocilizumab in refractory or relapsing giant cell arteritis, with case examples from consecutive patients who accessed the funding between August 2018 and April 2021. A total of 16 patients were identified: 11 female and 5 male, with an average age of 72.4 (range 61-82) years, with a majority of 11 ethnically white. The central assessing hub is St George's University Hospitals NHS Foundation Trust Hospital, serving a population of 1.3 million in the south of England. This is the first large case series looking into the impact of the establishment of a regional clinical pathway for the new tocilizumab funding. CONCLUSIONS: The case series demonstrates that the use of tocilizumab has reduced both the duration and the dose of corticosteroids in these 16 cases (mean prednisolone reduction 20.4 mg: 95% CI 13.0-27.8 mg), with 50% of patients continuing on tocilizumab after the initial 12 month funding period. The disease course, patterns of response, and maintenance of remission are discussed, and we describe the benefits of replicating this hub and spoke tocilizumab pathway in other centers.
Asunto(s)
Arteritis de Células Gigantes , Humanos , Masculino , Femenino , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Arteritis de Células Gigantes/tratamiento farmacológico , Anticuerpos Monoclonales Humanizados/uso terapéutico , Prednisolona/uso terapéuticoRESUMEN
Introduction: The Covid-19 pandemic brought significant disruption to post-graduate medical education. Lecture-based training days were rapidly converted to webinars. This study aims to assess the perceptions of digital training in internal medical trainees. Methods: IMTs (internal medicine trainees) nationally were surveyed on their perceptions of digital training, ease of access, engagement, and interactivity via a 10-item questionnaire. A mixed-method approach using qualitative and quantitative questions was used. Likert scales were analysed using a mean result of above 3 to indicate agreement. Results: 359 trainees responded. Trainees agreed that they preferred digital training to face-to-face teaching (mean 3.68); digital training was more engaging (mean 4.25), easier to access (mean 4.49), and as effective for learning as face-to-face teaching (mean 4.69). The most reported advantages were no travel (89%) and the ability to watch later on (88%). 63% of trainees reported loss of social interaction as a disadvantage. Discussion: This survey suggests that digital teaching has a potential role in IMT training beyond the pandemic.
RESUMEN
Surgery in the neonatal period presents challenges, especially in preterm infants weighing <1 kg. Their small size, minimal reserves and physiological immaturity means attention to detail and careful monitoring is critical to avoid cardiovascular instability; maintaining fluid balance and metabolic stability is also problematic due to often limited vascular access and small blood volumes. Developments in technology have meant that cardiovascular parameters such as heart rate, blood pressure and oxygen saturations are all routinely and continuously monitored before and during surgery.We have been exploring the role of continuous glucose monitoring (CGM) for metabolic monitoring and management of glucose control in very preterm infants (24-32 weeks gestation). In this paper, we report on a preterm infant who uniquely underwent surgery while wearing a continuous glucose monitor, blinded to the clinical team. This case highlights the metabolic vulnerability of these babies and a possible role for real-time CGM during surgical procedures.